Published on April 3, 2017

Indian pharma industry is expected to register moderate growth largely owing to increased regulatory inspection and consolidation of supply chain in the US market.

As per source related to Industry that continued regulatory interventions in domestic market are probable to put some pressure in near term though long-term growth prospects for domestic pharmaceutical market remain healthy given increasing penetration, accessibility and continued new launches.

Report said the domestic pharma industry has gained adequate scale and drug development capabilities over the last decade of growth which would keep them in good stead to capture new opportunities in the US market.

The last couple of years have been weaker for the sector. It has declined by 25 percent from five-year 2012-16. As per market analyst the upcoming market sentiment is bullish and India’s pharma sector’s growth story looks positive with the innovative product development.